Severity
Moderate
FDA Drug recall · Reported October 23, 2019
Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thickness.
Aurobindo Pharma USA Inc. recalled Dextroamphetamine Sacharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Ampheta… - a moderate-severity action.
Dextroamphetamine Sacharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Ampheta… was recalled by Aurobindo Pharma USA Inc. in October 23, 2019. Reason: Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thic…. Check the official notice for the remedy. Verify recall #D-0143-2020 with the FDA Drug before acting.
The recall
Aurobindo Pharma USA Inc. issued this moderate-severity FDA Drug recall-Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thic….
Sourced from official FDA Drug enforcement records. Verify recall #D-0143-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0143-2020) was formally reported on October 23, 2019, with the manufacturer initiating the action on September 19, 2019. It is classified under Moderate severity (Class II), with a current status of Terminated. Aurobindo Pharma USA Inc. is listed as the recalling firm, operating out of East Windsor, NJ. Federal records list the affected scope as 11,129 100-count bottles.
The documented reason for this recall is: Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thickness. Distribution data in the federal record shows the product reached: Nationwide in the US. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
11,129 100-count bottles
Related Recalls
6
5 from same agency
Dextroamphetamine Sacharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Mixed Salts of a single Entity Amphetamine Product), 20mg, 100-count bottle, RX Only, Distributed by: Aurobindo Pharma USA Inc., Dayton, NJ 08810, NDC 13107-073-01
Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thickness.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0143-2020 |
| Date reported | October 23, 2019 |
| Date initiated | September 19, 2019 |
| Recalling firm | Aurobindo Pharma USA Inc. |
| Firm location | East Windsor, NJ |
| Affected scope | 11,129 100-count bottles |
| Distribution | Nationwide in the US |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported October 23, 2019. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.